CDKN2A and pancreatic adenocarcinoma: Furthermore, we have elucidated the impact of KRAS, P53, and CDKN2A mutations on pancreatic adenocarcinoma prognosis, with CDKN2A mutation serving as a potential prognostic factor independent of anoikis.